API
< Back to all clusters
[HEALTH] · United States, Switzerland · 26 sources

started · updated

Novartis Zolgensma gene therapy under FDA investigation for tumor risks

The US Food and Drug Administration (FDA) is investigating potential cancer risks associated with Novartis’ gene therapy, Zolgensma, which is used to treat spinal muscular atrophy (SMA) in children. Novartis has reported nine cases of tumors in patients treated with the therapy since its approval in 2019.

In two of these cases, investigators found evidence of the viral vector DNA integrating into the patients' DNA, a process known as insertional oncogenesis. In three cases, the GLI1 oncogene was reportedly involved, which can drive cancer growth. The tumors identified have appeared in the brain, nerves, spine, and kidneys.

Despite these findings, the FDA stated that the overall benefits of the therapy continue to outweigh the potential risks for its approved uses. More than 6,000 patients have received Zolgensma worldwide through clinical trials and commercial treatments. The agency is currently evaluating whether further regulatory actions are necessary and is reviewing long-term safety monitoring protocols.

Entities

FDA · Novartis · SMA Europe · SMA UK · Zolgensma · spinal muscular atrophy

Claims

What the coverage asserts, and how many sources carry each claim.

Sources